FDA Science Board Previews Device “Critical Path” R&D Opportunity List
This article was originally published in The Gray Sheet
Executive Summary
Peripheral vasculature imaging is poised to be an early beneficiary of FDA's "critical path" initiative, CDRH Office of Science & Engineering Director Larry Kessler told the agency's Science Board April 22
You may also be interested in...
NCI Unveils Nanotech Initiative, Looks To Award Molecular Imaging Grants
Molecular imaging and early detection grants will be awarded by the National Cancer Institute as part of a broader $144.3 mil. nanotechnology initiative announced Sept. 13
NCI Unveils Nanotech Initiative, Looks To Award Molecular Imaging Grants
Molecular imaging and early detection grants will be awarded by the National Cancer Institute as part of a broader $144.3 mil. nanotechnology initiative announced Sept. 13
FDA Critical Path Office Would Define Up To Four “Opportunities” Per Year
FDA envisions creating an Office of Critical Path Opportunities over the next few months to coordinate with industry, academics, clinicians and the general public in proposing an annual list of translational research priorities to spur product development